Fatal Fungal Infection Has Unique Growth Patterns
|
By LabMedica International staff writers Posted on 08 Sep 2016 |

Image: A microscopic appearance of non-aggregate-forming isolates (A) and aggregate-forming isolates (B) of Candida auris in phosphate buffered saline suspensions (Photo courtesy of Public Health England).
The multidrug-resistant yeast Candida auris, which has caused fatal infections in some hospitalized patients, has at least two different growth patterns and some of its strains are as capable of causing disease as the most invasive type of yeast called Candida albicans.
Normally, a yeast copies itself and divides during growth, but the C. auris samples differ in their growth characteristics in the laboratory, with a proportion failing to separate after budding, resulting in the formation of large clumps of cells that could not be physically disrupted.
Mycology specialists at the Public Health England Mycology Reference Laboratory (Bristol, UK) characterized 12 C. auris isolates by ribosomal DNA (rDNA) gene sequencing targeting the 28S rRNA or by internal transcribed spacer 1 (ITS1) regions and matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) analysis or by a combination of the two methods.
The scientists compared the pathogenicity, or disease-causing potential, of the C. auris samples taken from patients treated at six National Health Service hospitals in England with samples of other disease-causing Candida species. To do so, they injected young wax moth larvae (called Galleria mellonella, an insect model used to study human infection) with the assorted Candida samples to measure progression of disease. The investigators also found strain-specific differences in the behavior of C. auris, with the clumped strains being less capable of causing disease than the ones that did not clump. The strains that did not clump were as capable of causing disease as another type of Candida called C. albicans, which is currently believed to have the most disease-causing potential in the Candida family.
Elizabeth Johnson, PhD, director of the National Mycology Reference Laboratory and co-author of the study, said, “Despite receiving considerable attention since its first description, little is known concerning the disease-causing potential of this emerging fungal pathogen. We were surprised to find two very different growth forms of C. auris depending on the strain. We were also surprised by the virulence of this species because in most other types of Candida, the ability to cause disease relates to the organism's ability to form hyphae (fine, branching tube-like structures). C. auris is not able to form these hyphae in the laboratory or in the insect infection model, so we would have predicted reduced ability to cause disease.” The study was published on August 18, 2016, in the journal mSphere.
Related Links:
Public Health England Mycology Reference Laboratory
Normally, a yeast copies itself and divides during growth, but the C. auris samples differ in their growth characteristics in the laboratory, with a proportion failing to separate after budding, resulting in the formation of large clumps of cells that could not be physically disrupted.
Mycology specialists at the Public Health England Mycology Reference Laboratory (Bristol, UK) characterized 12 C. auris isolates by ribosomal DNA (rDNA) gene sequencing targeting the 28S rRNA or by internal transcribed spacer 1 (ITS1) regions and matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) analysis or by a combination of the two methods.
The scientists compared the pathogenicity, or disease-causing potential, of the C. auris samples taken from patients treated at six National Health Service hospitals in England with samples of other disease-causing Candida species. To do so, they injected young wax moth larvae (called Galleria mellonella, an insect model used to study human infection) with the assorted Candida samples to measure progression of disease. The investigators also found strain-specific differences in the behavior of C. auris, with the clumped strains being less capable of causing disease than the ones that did not clump. The strains that did not clump were as capable of causing disease as another type of Candida called C. albicans, which is currently believed to have the most disease-causing potential in the Candida family.
Elizabeth Johnson, PhD, director of the National Mycology Reference Laboratory and co-author of the study, said, “Despite receiving considerable attention since its first description, little is known concerning the disease-causing potential of this emerging fungal pathogen. We were surprised to find two very different growth forms of C. auris depending on the strain. We were also surprised by the virulence of this species because in most other types of Candida, the ability to cause disease relates to the organism's ability to form hyphae (fine, branching tube-like structures). C. auris is not able to form these hyphae in the laboratory or in the insect infection model, so we would have predicted reduced ability to cause disease.” The study was published on August 18, 2016, in the journal mSphere.
Related Links:
Public Health England Mycology Reference Laboratory
Latest Microbiology News
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Channels
Clinical Chemistry
view channel
Blood Test Detects Testicular Cancer Missed by Standard Markers
Testicular cancer most often affects adolescents and young adults and is highly treatable when found early. Diagnosis can be difficult when tumors do not produce sufficient levels of standard blood-based... Read more
Routine Blood Tests Identify Biomarkers Linked to PTSD
Post-traumatic stress disorder (PTSD) is associated with a range of chronic physical health conditions and affects multiple organ systems. Clinical laboratories routinely measure blood analytes that reflect... Read moreMolecular Diagnostics
view channel
CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously
Respiratory virus co-circulation complicates differential diagnosis, as overlapping symptoms can obscure etiology. Multiplex testing typically depends on multiple enzymes or fluorophores and multistep... Read more
Multi-Omic Assay Predicts Recurrence and Radiation Benefit in Early Breast Cancer
Early-stage invasive breast cancer is frequently managed with breast-conserving surgery followed by adjuvant radiation therapy, but the magnitude of benefit from radiation varies among patients.... Read more
Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
Despite decades of effective drug regimens, tuberculosis remains the leading cause of death from an infectious disease, driven in part by limited access to accurate, rapid testing. Conventional diagnostics... Read more
Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
Differentiating schizophrenia from bipolar I disorder in symptomatic patients is challenging because early presentations often overlap. Current diagnostic pathways rely heavily on subjective assessments... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
Sepsis remains a time-critical condition in which rapid risk assessment is often hindered by reliance on centralized laboratory testing. The global burden is substantial, with an estimated 166 million... Read more
Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
Accurate laboratory diagnosis of early Lyme disease remains challenging because serologic responses may be limited soon after infection. Missed detection at this stage can delay evaluation and management... Read morePathology
view channel
New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read moreTechnology
view channel
Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
Risk stratification for breast cancer remains imprecise, as population-based models and breast density can over- or underestimate individual risk, potentially leading to over- or under-screening.... Read more







